0
CNS Pharmaceuticals, Inc. Banner Image

CNS Pharmaceuticals, Inc. has reached its limit for free report views

Work for CNS Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

CNS Pharmaceuticals, Inc.

  • Ticker CNSP
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
CNS Pharmaceuticals, Inc. Logo Image
  • 1-10 Employees
  • Based in Houston, Texas
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-howMore from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.
CNS Pharmaceuticals, Inc.

Most Recent Annual Report

CNS Pharmaceuticals, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. CNS Pharmaceuticals, Inc. has reached its limit for free report views.